CORONA Remedies DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage
	0.76×	0.77×
	0.95×	0.94×
	18.4%	18.2%
	1.16×	1.16×
	1.55×	1.61×
	23.9%	24.7%
	24.8%	24.8%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

CORONA₹2,217.40

CORONA Remedies Ltd.

· Pharma & Health

₹ CrorePeersERIS MANKIND APLLTD ALIVUS AKUMS AGARWALEYE HCG ADVENZYMESMcap ₹13,562 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY26 31/03/2026	Last 12M 30/09/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.77	0.76
Interest Burden (Pretax/EBIT) ×	0.94	0.95
EBIT Margin %	18.21	18.36
Asset Turnover ×	1.16	1.16
Financial Leverage (Assets/Equity) ×	1.61	1.55
ROE (5-step product, year-end total equity) %	24.69	23.85
ROE (owners' profit / average owners' equity) %	24.79	24.79

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.